Drugs / GSK1572932A
GSK1572932A
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01498172 | Jan 2012 → Feb 2015 | urinary bladder cancer | Patrice Jichlinski | Completed | No outcome recorded |
| Phase 1 | NCT00455572 | May 2007 → Aug 2013 | non-small cell lung carcinoma | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00290355 | May 2002 → Jul 2011 | non-small cell lung carcinoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00480025 | Oct 2007 → Dec 2013 | non-small cell lung carcinoma | GlaxoSmithKline | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK1572932A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00455572 ↗ |
| Known as | GSK 249553 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00290355 ↗ |
| Known as | MAGE-A3 ASCI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01498172 ↗ |
| Known as | recMAGE-A3 + AS15 ASCI | “In this study, the investigators would like to assess how intravesical BCG schedules after immunization of non muscle invasive bladder patients with the recMAGE-A3 protein,...” NCT01498172 ↗ |
| Modality | Vaccine | “GSK 249553 vaccine” NCT00290355 ↗ |
| Route | Intramuscular | “The study treatment will be administered by intramuscular injection” NCT00290355 ↗ |